Press release
ERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes
ERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes
Lyon (France), May 23, 2023 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has published the exemption document relating to the proposed combination with Pherecydes.
The document may be consulted on the company’s website.